Takeda Brings Oral Narcolepsy Therapy ORZEYFUL to Japan and China
Takeda said ORZEYFUL (oveporexton) is now available in Japan and China for narcolepsy type 1. The oral therapy is an OX2R agonist designed to address the orexin deficiency that underlies the condition. Clinicians in both countries can now prescribe this type of treatment.
Takeda has made oveporexton, marketed as ORZEYFUL, available in Japan and China for narcolepsy type 1. The company describes it as a first-in-class oral tablet that acts as an OX2R agonist. It is intended to address the orexin deficiency thought to underlie NT1. Clinicians in both markets can now prescribe this new class of therapy.
The announcement comes from Takeda, a company listed in Tokyo and New York. The release frames the launch as first access for prescribers in these countries to this treatment approach. No pricing, eligibility, or post-approval data were included in the provided material.
For people with NT1 in Japan and China, an oral option from a new drug class could broaden treatment choices and may reduce reliance on symptom-focused approaches, though actual benefit will depend on access, cost, and clinical fit. Clinicians may gain another mechanism-based tool, while caregivers and health systems could see changes in prescribing pathways if uptake grows. Long-term societal impact remains uncertain until real-world safety, affordability, and availability are clearer.